Abstract:Nanocarriers for delivery of phytoconstituents against lung cancer. Lung cancer, the second leading cause of cancer‐related deaths, accounts for a substantial portion, representing 18.4% of all cancer fatalities. Despite advances in treatment modalities such as chemotherapy, surgery, and immunotherapy, significant challenges persist, including chemoresistance, non‐specific targeting, and adverse effects. Consequently, there is an urgent need for innovative therapeutic approaches to overcome these limitations. Natural compounds, particularly phytoconstituents, have emerged as promising candidates due to their potent anticancer properties and relatively low incidence of adverse effects compared to conventional treatments. However, inherent challenges such as poor solubility, rapid metabolism, and enzymatic degradation hinder their clinical utility. To address these obstacles, researchers have increasingly turned to nanotechnology‐based drug delivery systems (DDS). Nanocarriers offer several advantages, including enhanced drug stability, prolonged circulation time, and targeted delivery to tumor sites, thereby minimizing off‐target effects. By encapsulating phytoconstituents within nanocarriers, researchers aim to optimize their bioavailability and therapeutic efficacy while reducing systemic toxicity. Moreover, the integration of nanotechnology with phytoconstituents allows for a nuanced understanding of the intricate molecular pathways involved in lung cancer pathogenesis. This integrated approach holds promise for modulating key cellular processes implicated in tumor growth and progression. Additionally, by leveraging the synergistic effects of phytoconstituents and nanocarriers, researchers seek to develop tailored therapeutic strategies that maximize efficacy while minimizing adverse effects. In conclusion, the integration of phytoconstituents with nanocarriers represents a promising avenue for advancing lung cancer treatment. This synergistic approach has the potential to revolutionize current therapeutic paradigms by offering targeted, efficient, and minimally toxic interventions. Continued research in this field holds the promise of improving patient outcomes and addressing unmet clinical needs in lung cancer management.

Review Deciphering the Potential of Nanotherapeutics in Lung Cancer Management

Bio-Nanocarriers for Lung Cancer Management: Befriending the Barriers

Nano-based targeted drug delivery for lung cancer: therapeutic avenues and challenges

Role of Nanoformulations in the Treatment of Lung Cancer

Nanomaterials for Diagnosis and Treatment of Lung Cancer: A Review of Recent Patents

Nanotechnology and Nanomedicine: A Promising Avenue for Lung Cancer Diagnosis and Therapy

Nanoemulsion therapy: A paradigm shift in lung cancer management

Empowering lung cancer treatment: Harnessing the potential of natural phytoconstituent‐loaded nanoparticles

A novel therapeutic outlook: Classification, applications and challenges of inhalable micron/nanoparticle drug delivery systems in lung cancer (Review)

Recent nanotechnological aspects and molecular targeting strategies for lung cancer therapy

Advances in Lung Cancer Treatment Using Nanomedicines

Nanoengineered Polymers and Other Organic Materials in Lung Cancer Treatment: Bridging the Gap Between Research and Clinical Applications

Moving beyond traditional therapies: the role of nanomedicines in lung cancer

Nano-mediated strategy for targeting and treatment of non-small cell lung cancer (NSCLC)

Nanostructured lipid carriers (NLCs): A promising candidate for lung cancer targeting

Nanoparticles advanced from preclinical studies to clinical trials for lung cancer therapy

Nanocarrier-Mediated Drug Delivery via Inhalational Route for Lung Cancer Therapy: A Systematic and Updated Review

Emerging trends in the novel drug delivery approaches for the treatment of lung cancer

Nanotechnology for the theranostic opportunity of breast cancer lung metastasis: recent advancements and future challenges

Nanotechnology based therapeutics for lung disease

Nanotechnology: Breaking the Current Treatment Limits of Lung Cancer